Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.62 |
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.60 |
| ▸ | INSR | P06213 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30184091 | 0.99 | ALK (0.62) | ALKMAP4K1INSR | |
| SCHEMBL30446889 | 0.95 | MAP4K1 (0.58) | ALKMAP4K1INSR | |
| Hydrochloric Acid SCHEMBL30446345 | 0.94 | MAP4K1 (0.57) | ALKMAP4K1INSR | |
| SCHEMBL25947724 | 0.90 | ALK (0.61) | ALKMAP4K1INSR | |
| Hydrochloric Acid SCHEMBL29172291 | 0.89 | ALK (0.60) | ALKMAP4K1INSR | |
| SCHEMBL32685266 | 0.88 | MAP4K1 (0.52) | ALKMAP4K1INSR | |
| Hydrochloric Acid SCHEMBL30446368 | 0.88 | MAP4K1 (0.52) | ALKMAP4K1INSR | |
| SCHEMBL25337779 | 0.88 | MAP4K1 (0.62) | ALKMAP4K1INSR | |
| SCHEMBL30183975 | 0.88 | MAP4K1 (0.62) | ALKMAP4K1INSR | |
| SCHEMBL20214436 | 0.87 | MAP4K1 (0.77) | ALKMAP4K1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | claimed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | claimed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | claimed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | ALK 150/4885MAP4K1 23/4885INSR 630/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | ALK 2067/4885MAP4K1 1/4885INSR 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.